Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of molidustat versus darbepoetin alfa for anemia in pre-dialysis chronic kidney disease
2013-001190-24Phase 2Terminated
- Sponsor
- Bayer
- Start
- Aug 2013
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of molidustat and darbepoetin alfa in anemia of chronic kidney disease (2 arms), sponsored by Bayer. Primary endpoint: Change in local laboratory haemoglobin level from baseline. Started Aug 2013; status: terminated.
02
Drugs
molidustatdarbepoetin alfa
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on 2013-001190-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001190-24.